NCT03189498View on ClinicalTrials.gov

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 6, 2017

Conditions
Renal Insufficiency
Interventions
DRUG

JNJ-64041575

All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.

Trial Locations (2)

81241

APEX GmbH, München

Unknown

CRS Clinical Research Services Kiel, Kiel

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT03189498 - A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function | Biotech Hunter | Biotech Hunter